Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. (CRDL.TO) Financial Performance & Income Statement Overview
Review Cardiol Therapeutics Inc. (CRDL.TO) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Cardiol Therapeutics Inc. (CRDL.TO) Income Statement & Financial Overview
Analyze Cardiol Therapeutics Inc.’s CRDL.TO earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $61908.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$61908.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $3.76M | $4.23M | $3.75M | $2.71M |
| SG&A Expenses | $4.65M | $5.76M | $10.39M | $4.97M |
| Operating Expenses | $8.43M | $9.99M | $14.14M | $7.68M |
| Total Costs & Expenses | $8.43M | $9.99M | $14.14M | $7.74M |
| Interest Income | $248269.00 | $306775.00 | $201864.00 | $307409.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $24986.00 | $48493.00 | $201090.00 | $61908.00 |
| EBITDA | -$8.40M | -$9.94M | -$13.94M | -$7.68M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$8.43M | -$9.99M | $0.00 | -$7.74M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $141410.00 | $1.81M | $1.41M | $1.15M |
| Income Before Tax | -$8.29M | -$8.18M | -$12.73M | -$6.59M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.29M | -$8.18M | -$12.73M | -$6.59M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.10 | -$0.10 | -$0.18 | -$0.10 |
| Diluted EPS | -$0.10 | -$0.10 | -$0.18 | -$0.10 |
| Weighted Avg Shares Outstanding | $82.61M | $81.78M | $69.84M | $68.75M |
| Weighted Avg Shares Outstanding (Diluted) | $82.61M | $81.78M | $69.84M | $68.75M |
Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$8.43M in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$8.40M. Net income dropped to -$8.29M, keeping EPS at -$0.10. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan